StevenDReichMD

PubMed

• 18 citations
  Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.
  Daniela A. Bota, Warren P. Mason, Santosh Kesari, Rajiv Magge, Benjamin Winograd, Ileana Elias, Steven D. Reich, Nancy Levin, Mohit Trikha, Annick Desjardins> ;Neuro-Oncology Advances. 2021 Jan 1
• 53 citations
  A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
  Andrew Spencer, Simon J. Harrison, Jeffrey A. Zonder, Ashraf Z. Badros, Jacob P. Laubach, Krystal Bergin, Amit Khot, Todd M. Zimmerman, Dharminder Chauhan, Nancy Levin...> ;British Journal of Haematology. 2018 Jan 1
• 30 citations
  First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors
  Geoffrey I. Shapiro, Ulka N. Vaishampayan, Patricia LoRusso, Jeremy Barton, Steven Y. Hua, Steven D. Reich, Ronald L. Shazer, Carrie T. Taylor, Dawei Xuan, Hossein Bor...> ;Investigational New Drugs. 2017 Jan 9
• 46 citations
  Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
  Simon J. Harrison, Paul N. Mainwaring, Timothy J. Price, Michael Millward, Peeter Padrik, Craig Underhill, Paul Cannell, Steven D. Reich, Mohit Trikha, Andrew Spencer> ;Clinical Cancer Research. 2016 Sep 15
• 37 citations
  Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
  Nancy Levin, Andrew Spencer, Simon J. Harrison, Dharminder Chauhan, Francis Burrows, Kenneth C. Anderson, Steven D. Reich, Paul G. Richardson, Mohit Trikha> ;British Journal of Haematology. 2016 Sep 1
• 42 citations
  A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve...
  Jianqing Lin, Marianna Zahurak, Tomasz M. Beer, Charles J. Ryan, George Wilding, Paul Mathew, Michael J. Morris, Jennifer A. Callahan, Gilad Gordon, Steven D. Reich, M...> ;Urologic Oncology. 2013 Jul 1
• 70 citations
  Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
  Monica M. Mita, Matthew A. Spear, Lorrin K. Yee, Alain C. Mita, Elisabeth I. Heath, Kyriakos P. Papadopoulos, Kristine C. Federico, Steven Reich, Ofelia Romero, Lisa M...> ;Clinical Cancer Research. 2010 Dec 1
• A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium tr...
  Lin J, Beer TM, Ryan CJ, Mathew P, Wilding G, Morris M, Callahan JA, Gordon G, Reich S, Carducci MA> ;J. Clin. Oncol.. 2009-05-20
• 53 citations
  Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors.
  Sarah A. Lowndes, Avril Adams, Anthony Timms, Nita Fisher, Jon Smythe, Suzanne M. Watt, Simon Joel, Fernando Donate, Carolyn Hayward, Steven Reich, Mark R. Middleton, ...> ;Clinical Cancer Research. 2008 Nov 15
• 37 citations
  The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  Francis J. Giles, William T. Bellamy, Zeev Estrov, Susan O'Brien, Srdan Verstovsek, Farhad Ravandi, Miloslav Beran, Paul Bycott, Yazdi K. Pithavala, Heidi Steinfeldt, ...> ;Leukemia Research. 2006 Jul 1
• Phase I study of ATN-224 in patients (pts) with advanced solid tumours.
  Lowndes SA, Adams A, Timms A, Middleton M, Hayward C, Reich SD, Mazar AP, Harris AL> ;J. Clin. Oncol.. 2006-06-20
• 386 citations
  Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results
  Hope S. Rugo, Roy S. Herbst, Glenn Liu, John W. Park, Merrill S. Kies, Heidi Steinfeldt, Yazdi K. Pithavala, Steven D. Reich, James L. Freddo, George Wilding> ;Journal of Clinical Oncology. 2005 Aug 20
• 197 citations
  Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patie...
  Glenn Liu, Hope S. Rugo, George Wilding, Teresa M. Mcshane, Jeffrey L. Evelhoch, Chaan Ng, Edward F. Jackson, Frederick Kelcz, Benjamin M. Yeh, Fred T. Lee, Chusilp Ch...> ;Journal of Clinical Oncology. 2005 Aug 20
• AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer ...
  Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, Bolte O, Steinfeldt H, Reich SD, Motzer R> ;J. Clin. Oncol.. 2005-06-01
• First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.
  Plummer R, Middleton M, Wilson R, Jones C, Evans J, Robson L, Steinfeldt H, Kaufman R, Reich S, Calvert AH> ;J. Clin. Oncol.. 2005-06-01
• Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors.
  Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Pithavala YK, McShane TM, Steinfeldt HM, Reich SD, Wilding G> ;J. Clin. Oncol.. 2004-07-15
• Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tu...
  Robert F, Garrett C, Dinwoodie WR, Sullivan DM, Bishop M, Amantea M, Zhang M, Reich SD> ;J. Clin. Oncol.. 2004-07-15
• 92 citations
  Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial☆
  Peter Heald, Marilyn Mehlmauer, Ann G. Martin, Constance A. Crowley, Richard C. Yocum, Steven D. Reich> ;Journal of the American Academy of Dermatology. 2003 Nov 1
• 104 citations
  Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non–Small-Cell Lun...
  Fadlo R. Khuri, James R. Rigas, Robert A. Figlin, Richard J. Gralla, Dong M. Shin, Reginald F. Munden, Nikolaus Fox, Mi Ra Huyghe, Yin Kean, Steven D. Reich, Waun Ki Hong> ;Journal of Clinical Oncology. 2001 May 15
• Low-dose chemotherapy with vinblastine and methotrexate in childhood desmoid tumors.
  Reich S, Overberg-Schmidt US, Bührer C, Henze G> ;J. Clin. Oncol.. 1999-03-01
• In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.
  Kirkwood JM, Ernstoff MS, Trautman T, Hebert G, Nishida Y, Davis CA, Balzer J, Reich S, Schindler J, Rudnick SA> ;J. Clin. Oncol.. 1990-06-01
• 30 citations
  A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma.
  Charles E. Welander, Howard D. Homesley, Steven D. Reich, Elizabeth A. Levin> ;American Journal of Clinical Oncology. 1988 Aug 1
• 51 citations
  Phase I/II Study of Recombinant Interferon Gamma in Advanced Renal Cell Carcinoma
  Marc B. Garnick, Steven D. Reich, Barbara Maxwell, Sherrie Coval-Goldsmith, Jerome P. Richie, Seth A. Rudnick> ;The Journal of Urology. 1988 Feb 1
• A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma.
  Ernstoff MS, Trautman T, Davis CA, Reich SD, Witman P, Balser J, Rudnick S, Kirkwood JM> ;J. Clin. Oncol.. 1987-11-01
• 11 citations
  Recombinant gamma interferon in advanced breast cancer: a phase II trial.
  Hyman B. Muss, Mary E. Caponera, Patricia J. Zekan, Don V. Jackson, John J. Stuart, Frederick Richards, M. Robert Cooper, Elizabeth A. Levin, Steven D. Reich, Robert L...> ;Investigational New Drugs. 1986 Jan 1
• Join now to see all